A prospective study comparing the effects of intramyometrial and continuous intravenous injection of oxytoci
- Conditions
- none
- Registration Number
- JPRN-jRCTs041210153
- Lead Sponsor
- aruse Satoshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 24
1. Preoperative ASA-PS (ASA physical status) 2
2. Singleton
3. 37 weeks or more gestation
4.Patients scheduled for elective cesarean section with spinal stem anesthesia
5.Those who are between 20 and 40 years old at the time of obtaining consent.
6.Those who have given their consent for this study by signing the consent form.
1. Obvious obstetric diseases (uterine fibroids, uterine adenomyosis, endometriotic cysts, giant baby, excessive amniotic fluid, gestational hypertension), cardiac diseases
2. Patients with obvious obstetrical diseases (uterine fibroids, endometrial cysts, giant babies, excessive amniotic fluid, gestational hypertension), cardiac diseases, blood coagulation abnormalities, and spinal diseases that would make it difficult to perform spinal stem anesthesia
Those who are in labor.
3. Those whose water has broken.
4.Those with abnormal placental position
5. Those with other placental abnormalities
6. Those with multiple pregnancies
7.Those with uterine malformation
8.Those with oxytocin allergy
9. Obesity (BMI above 30 at 35-36 weeks gestation)
10. Those who have had 3 or more deliveries
11.Those who have a history of postpartum hemorrhage.
12.Those who are judged by the principal investigator or sub-investigator to be inappropriate for inclusion in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total blood loss from intraoperative to 2 hours after returning to the ward
- Secondary Outcome Measures
Name Time Method 1. frequency of postpartum hemorrhage (total blood volume >1000 mL)<br>2. degree of uterine contractions (2 hours after return to the ward)<br>3. presence of additional oxytocin and total additional dose (from intraoperative to 2 hours after return to the ward) 4. uterine contractions other than oxytocin (methyl erythrocyte)<br>4. use of uterine contractions other than oxytocin (methylergometrine, prostaglandin F2)<br>5. surgical intervention (B-Lynch suture, balloon tamponade, gauze tamponade, vascular ligation, hysterectomy, arterial embolization (Interventional Radiology:IVR))<br>6. presence and frequency of fundus massage<br>7.Number of cases of refractory flaccid hemorrhage<br>8.Blood transfusion<br>9.Length of hospital stay<br>10. total dose of phenylephrine after delivery of the child<br>11. changes in vital signs (blood pressure, heart rate, cardiac output, and cardiac output per cycle)